Krystal Biotech Inc Earnings

Krystal Biotech Inc’s revenue jumped 94.88% since last year same period to $88.18Mn in the Q1 2025. On a quarterly growth basis, Krystal Biotech Inc has generated -3.24% fall in its revenue since last 3-months.

Krystal Biotech Inc’s net profit jumped 3734.01% since last year same period to $35.73Mn in the Q1 2025. On a quarterly growth basis, Krystal Biotech Inc has generated -21.43% fall in its net profits since last 3-months.

Krystal Biotech Inc’s net profit margin jumped 1867.38% since last year same period to 40.52% in the Q1 2025. On a quarterly growth basis, Krystal Biotech Inc has generated -18.8% fall in its net profit margins since last 3-months.

Krystal Biotech Inc’s price-to-earnings ratio after this Q1 2025 earnings stands at 31.68.

Krystal Biotech Inc’s earning per share (EPS) estimates for the current quarter stand at 1.03 - a -44.39% fall from last quarter’s estimates.

Krystal Biotech Inc’s earning per share (EPS) estimates for the current year stand at 1.03.

Krystal Biotech Inc’s earning per share (EPS) jumped 3887.33% since last year same period to 1.2 in the Q1 2025. This indicates that the Krystal Biotech Inc has generated 3887.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Krystal Biotech Inc’s return on assets (ROA) stands at 0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Krystal Biotech Inc’s return on equity (ROE) stands at 0.14.